(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
My Enterprising Excursion: Building a Startup - 2The capacity to understand people on a profound level: Exploring Life's Intricacies
- 3Strengthening through Wellness: Individual Preparation Achievement
- 42026 Golden Globes: How to watch, start time, TV channel, full nominee list and more
- 5Space Condos to Lift Your Metropolitan Living
- See the moon shine with Saturn in the southern sky after sunset Dec. 26
- Pick Your Number one sort of blossom
- The Specialty of Compromise: Examples from Reality
- Will your baby get a hep B vaccine? What RFK panel's ruling means.
- From Certificate to Dollars: College Majors with Extraordinary Monetary Prizes
- Best bar-b-que Style: Which One Is Your Number one?
- The Best Cell phone Brands for Tech Lovers
- Chinese mega embassy could bring security advantages, says No 10
- What to know about MIT professor Nuno Loureiro and the investigation into his shooting
